Skip to Content

Quest Diagnostics Inc DGX

Morningstar Rating
$140.45 −0.45 (0.32%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Quest Diagnostics Should Shake Off Last of the COVID-19 Disruption in 2024

Quest Diagnostics is a leading provider of independent diagnostic testing in the United States thanks to its network of roughly 2,300 patient service centers across the country. We think the company's size and cost advantage allow Quest to benefit from several secular trends, including the proliferation of diagnostic tests and greater clinical reliance on personalized therapies. Additionally, we expect that Quest will see a reprieve from Medicare-related pricing pressure as regulators tinker with the method for setting lab test reimbursement rates.

Price vs Fair Value

DGX is trading at a 344% premium.
Price
$140.90
Fair Value
$653.00
Uncertainty
Medium
1-Star Price
$499.43
5-Star Price
$566.70
Economic Moat
Yhlbx
Capital Allocation
Dnpskxwtc

Bulls Say, Bears Say

Bulls

Advances in technology and personalized medicine are increasing the number of complex esoteric and gene-based tests available to patients. These tests generally carry a higher profit margin for Quest.

Bears

If a sizable number of hospital-based labs fail to comply with the data collection and reporting requirements of PAMA, the expected improvement in Medicare reimbursements may fail to materialize in 2025.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DGX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$140.90
Day Range
$138.77142.00
52-Week Range
$119.59145.62
Bid/Ask
$138.70 / $147.12
Market Cap
$15.60 Bil
Volume/Avg
1.0 Mil / 903,254

Key Statistics

Price/Earnings (Normalized)
16.18
Price/Sales
1.71
Dividend Yield (Trailing)
2.04%
Dividend Yield (Forward)
2.13%
Total Yield
3.81%

Company Profile

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Value
Total Number of Employees
48,000

Competitors

Valuation

Metric
DGX
LH
SHL
Price/Earnings (Normalized)
16.1814.8524.19
Price/Book Value
2.432.171.61
Price/Sales
1.711.441.48
Price/Cash Flow
11.2611.6110.86
Price/Earnings
DGX
LH
SHL

Financial Strength

Metric
DGX
LH
SHL
Quick Ratio
0.780.580.78
Current Ratio
0.970.880.94
Interest Coverage
7.314.035.95
Quick Ratio
DGX
LH
SHL

Profitability

Metric
DGX
LH
SHL
Return on Assets (Normalized)
7.33%6.77%4.07%
Return on Equity (Normalized)
15.76%13.92%7.01%
Return on Invested Capital (Normalized)
9.73%8.99%4.52%
Return on Assets
DGX
LH
SHL
See how this stock stacks up to its competitors with Morningstar Investor

Diagnostics & Research Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
RnlnyhrnMlrm$204.5 Bil
Danaher Corp
DHR
CymnsfvyZkxmt$177.8 Bil
IDEXX Laboratories Inc
IDXX
DjnydtscRwqds$39.4 Bil
IQVIA Holdings Inc
IQV
GppxyzcrlGslvrtj$37.7 Bil
Agilent Technologies Inc
A
RpqqrbvsgkGwxd$36.8 Bil
Mettler-Toledo International Inc
MTD
SxtwdgrtcNlytdg$28.9 Bil
Icon PLC
ICLR
YzylfpzsjKbckfz$26.3 Bil
Labcorp Holdings Inc
LH
ZbqqgfdjnTbpgrt$17.2 Bil
Waters Corp
WAT
GjssvmcwjYsrs$17.1 Bil
Illumina Inc
ILMN
GzlmyjdrVvtlkyr$16.8 Bil

Sponsor Center